好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

好色先生al Attainment in Patients with Frontotemporal Dementia and Primary Progressive Aphasia Compared to Other Dementia Syndromes
Aging and Dementia
P03 - (-)
089
BACKGROUND: Many dementia experts have observed the tendency for patients who develop bvFTD and PPA to be well-educated and successful individuals during early and mid-life, and this tendency seems to occur more frequently in bvFTD/PPA than what is typically seen in those with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). This observation could reflect true biologic differences, a secular effect or a referral bias. Since little epidemiologic data exists on bvFTD/PPA, we sought to explore whether high MEA is over-represented in the largest dataset of dementia subjects available in the US - the National Alzheimer Coordinating Center (NACC) database.
DESIGN/METHODS: Using MEA from the uniform data set in the NACC database (data entered 9/05 through 12/08), the mean MEA (in years) as well as frequencies of MEA being >16 were compared among bvFTD, PPA, AD and DLB.
RESULTS: Among 6457 subjects with one of the diagnoses of interest, 4816 (74.6%) had AD, 1045 (16.2%) had DLB, 388 (6.0%) had bvFTD, and 208 (3.2%) had PPA. The mean MEA (in years) was 14.0 for AD, 13.2 for DLB, 14.9 for bvFTD and 15.3 for PPA. The frequency for MEA >16 years was 22.0% for AD, 15.6% for DLB, 28.9% for FTD and 32.7% for PPA. Pair-wise tests between the groups are all statistically significant (p<0.001 after Bonferroni correction) except for PPA vs bvFTD.
CONCLUSIONS: The means and frequencies of high MEA are greater for bvFTD and PPA compared to AD and DLB. Whether a form of antagonistic pleiotropy and/or compensatory hyperfunctioning exists in some individuals who develop bvFTD or PPA, and what the biologic underpinnings might be, warrants further study.
Authors/Disclosures
Marla B. Bruns, MD, PhD (Unity Rehabilitation & Neurology At Ridgeway)
PRESENTER 		Dr. Bruns has nothing to disclose.
No disclosure on file
No disclosure on file
Meredith Wicklund, MD, FAAN (Mayo Clinic Arizona) The institution of Dr. Wicklund has received research support from Arizona Alzheimer's Consortium. The institution of Dr. Wicklund has received research support from NIH.
Elizabeth Loder, MD, MPH Dr. Loder has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. The institution of Dr. Loder has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The BMJ.
Walter A. Kukull, PhD, FAAN (Washington University of Medicine) The institution of Dr. Kukull has received research support from NIH/NIA. Dr. Kukull has a non-compensated relationship as a Associate editor with Alzheimer's and Dementia TRCI (journal) that is relevant to AAN interests or activities. Dr. Kukull has a non-compensated relationship as a Editorial board with Journal of American Geriatrics Soc that is relevant to AAN interests or activities.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.
No disclosure on file
M. M. Mesulam, MD, FAAN (Cogn Neur & Alzheimer Center, NW Univ) Dr. Mesulam has received publishing royalties from a publication relating to health care.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.